Qrons Inc. Stock

Equities

QRON

US74737F1012

Biotechnology & Medical Research

Market Closed - OTC Markets 12:55:39 2024-03-08 EST 5-day change 1st Jan Change
0.1855 USD -11.68% Intraday chart for Qrons Inc. -.--% -19.35%
Sales 2022 - Sales 2023 - Capitalization 3.14M 4.29M
Net income 2022 - 0 Net income 2023 - 0 EV / Sales 2022 -
Net Debt 2022 750K 1.02M Net Debt 2023 876K 1.2M EV / Sales 2023 -
P/E ratio 2022
-9.25 x
P/E ratio 2023
-3.94 x
Employees 3
Yield 2022 *
-
Yield 2023
-
Free-Float 25.86%
More Fundamentals * Assessed data
Dynamic Chart
Qrons Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Qrons Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Qrons Inc. Announces the Filing of A Provisional Patent Application in Furtherance of Its Neuronal and Infectious Disease Treatments Development, Including Sepsis CI
Qrons Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Qrons Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Qrons Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Qrons Inc. Auditor Raises 'Going Concern' Doubt CI
Qrons Files U.S. National Phase of Its Patent Application in Furtherance of Its Qs200 Product Candidate for Therapeutic Polypseudorotaxane Hydrogels CI
Qrons Announces a New Pre-Clinical Research Program to Test the Efficacy of Tellurium Based Compounds, in Combination with its QS200(TM) Product Candidate or Independently, in Treating Diffused Axonal Injuries and Antibiotic Resistant Bacteria and Sepsis CI
Qrons Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Qrons Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Qrons Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Qrons Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Qrons Inc. Auditor Raises 'Going Concern' Doubt CI
Qrons Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
More news
1 day-11.68%
3 months-19.35%
6 months-37.75%
Current year-19.35%
More quotes
Current year
0.16
Extreme 0.1557
0.24
1 year
0.16
Extreme 0.1557
0.75
3 years
0.16
Extreme 0.1557
1.00
5 years
0.16
Extreme 0.1557
2.95
10 years
0.16
Extreme 0.1557
3.90
More quotes
Managers TitleAgeSince
Founder 58 16-08-21
Chief Executive Officer 67 16-08-21
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chief Executive Officer 67 16-08-21
Founder 58 16-08-21
More insiders
Qrons Inc. is a biotechnology company. The Company is focuses on developing biotech products, treatments, and technologies to combat neuronal and infectious diseases with a focus on antibiotic resistant bacteria. It has developed a treatment that integrates proprietary, engineered mesenchymal stem cells (MSCs), 3D printable implant, smart materials, and a novel delivery system. The Company has developed two product candidates for treating penetrating and non-penetrating (concussion-like) traumatic brain injuries (TBIs), both integrating proprietary, anti-brain inflammation synthetic hydrogel and modified MSCs. QS100TM is an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200TM is an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions. The Company researches in the fields of regenerative medicine, tissue engineering and 3D printable hydrogels.
More about the company